Cargando…

Development of Schamberg's disease after SARS‐CoV‐2 vaccination

Schamberg's disease is one of a group of pigmented purpura diseases. We report a 43‐year‐old woman, who developed Schamberg’s disease after SARS‐CoV‐2 vaccination. Three days after vaccination, a purpuric eruption occurred on the lower extremities, extending to the buttocks, and subsided in 4 w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morimoto, Hiroki, Ogura, Yasuaki, Otsuka, Masaki, Hayano, Satoshi, Tokura, Yoshiki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347743/ http://dx.doi.org/10.1002/cia2.12247

Ejemplares similares

Development of IgA vasculitis after SARS‐CoV‐2 vaccination
por: Ogura, Yasuaki, et al.
Publicado: (2022)

Questionnaire Survey of Possible Association of Allergic Diseases with Adverse Reactions to SARS-CoV-2 Vaccination
por: Morimoto, Hiroki, et al.
Publicado: (2021)

Aminaphtone in the control of Schamberg's disease
por: de Godoy, José Maria Pereira, et al.
Publicado: (2009)

Le purpura de Schamberg
por: Akazane, Amal, et al.
Publicado: (2015)

Generalized Schamberg Disease in a Child
por: Park, Ji-Hye, et al.
Publicado: (2013)

SARS CoV2 vaccine and aphasia
por: sookaromdee, Pathum, et al.
Publicado: (2021)

SARS-CoV-2 incidence and vaccine escape
por: Thompson, Robin N, et al.
Publicado: (2021)

Effect of Vaccination on Transmission of SARS-CoV-2
por: Shah, Anoop S.V., et al.
Publicado: (2021)

Hemophagocytic lymphohistiocytosis and SARS-CoV-2 vaccination
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Post SARS-CoV-2 vaccination effluvium
por: Luu, Ngoc-Nhi C., et al.
Publicado: (2023)

SARS-CoV-2 vaccines and donor recruitment for FMT
por: Ianiro, Gianluca, et al.
Publicado: (2021)

A strategy for SARS-CoV-2 vaccination in Yemen
por: Nasser, Abdullah, et al.
Publicado: (2021)

Ophthalmologic compromise following SARS-CoV-2 vaccinations
por: Finsterer, Josef
Publicado: (2022)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Schamberg's disease: case report with therapeutic success by using colchicine
por: Cavalcante, Maria Lopes Lamenha Lins, et al.
Publicado: (2017)

Rutoside and Ascorbic Acid in the Treatment of Schamberg Pigmented Purpuric Dermatosis
por: Morquette, Alexandra J, et al.
Publicado: (2021)

SARS-CoV-2 vaccination for patients with inflammatory bowel disease
por: Garrido, Hannah M Garcia, et al.
Publicado: (2021)

Bell's palsy and SARS-CoV-2 vaccines—an unfolding story
por: Cirillo, Nicola, et al.
Publicado: (2021)

SARS-CoV-2 vaccination related hyperthyroidism of Graves’ disease
por: Shih, Shyang-Rong, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Ko, Humphrey H T
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Knol, Mirjam J, et al.
Publicado: (2022)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Franco-Paredes, Carlos
Publicado: (2022)

Tolerability and impact of SARS-CoV-2 vaccination in elite athletes
por: Hull, James H, et al.
Publicado: (2022)

Correspondence to: hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination
por: Sprute, Rosanne, et al.
Publicado: (2022)

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England
por: Harris, Ross J., et al.
Publicado: (2021)

Breakthrough SARS-CoV-2 Infections in Prison after Vaccination
por: Brinkley-Rubinstein, Lauren, et al.
Publicado: (2021)

SARS-CoV-2 vaccination triggered Guillain-Barre syndrome
por: Scorza, Fulvio A, et al.
Publicado: (2022)

Attitudes of vaccination service providers to the SARS-CoV-2 intranasal spray vaccine during the SARS-CoV-2 pandemic in China: A cross-sectional study
por: Cao, Yanlin, et al.
Publicado: (2023)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine
por: Zeng, Guangting
Publicado: (2022)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Lodge, Archie
Publicado: (2020)

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2
por: Chauhan, Anil, et al.
Publicado: (2020)

Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine
por: Peng, Pai, et al.
Publicado: (2021)

How Losing Sleep Following Vaccination May Weaken the Response to SARS-CoV Vaccines
por: Akhtar, Nasreen, et al.
Publicado: (2022)

Post-SARS-CoV-2-vaccine shoulder pain: Is it relevant to the vaccine injection? – Correspondence
por: Deng, Zhenhan, et al.
Publicado: (2022)

Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients
por: Hsu, Caroline M., et al.
Publicado: (2022)

Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases
por: Cozzani, Emanuele, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
por: Uriu, Keiya, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in pregnancy: a unique opportunity for equity
por: Kalafat, Erkan, et al.
Publicado: (2021)

Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0qnno315h1qpg8d62d52npl3ss